Published in Scand J Rheumatol on January 01, 2000
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med (1990) 3.37
Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med (1989) 3.33
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol (2001) 2.69
Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet (1986) 2.12
Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol (1987) 2.09
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum (2001) 2.00
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 1.98
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation. Cardiology (1998) 1.65
Cyclosporin for acute dermatomyositis. Lancet (1984) 1.61
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum (1999) 1.59
Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum (2000) 1.57
Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol (1990) 1.57
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol (2001) 1.51
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum (1994) 1.51
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum (1992) 1.44
Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum (1999) 1.42
Head and neck manifestations of Wegener's granulomatosis. Rhinology (2006) 1.41
Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol (1998) 1.39
[The risk profile of low-dose methotrexate in the therapy of chronic polyarthritis]. Dtsch Med Wochenschr (1992) 1.39
Treatment of Wegener's granulomatosis: the view from two non-nephrologists. Nephrol Dial Transplant (1994) 1.38
Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis. Semin Arthritis Rheum (2001) 1.38
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax (2008) 1.35
TAP deficiency syndrome. Clin Exp Immunol (2000) 1.35
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (2005) 1.33
Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen. J Immunol Methods (1988) 1.33
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) (2008) 1.32
Cryoglobulinemic vasculitis. Arthritis Rheum (1999) 1.31
[Antineutrophilic cytoplasmic antibodies (ANCA) in inflammatory rheumatic diseases: immunodiagnostic and immunopathogenetic aspects]. Z Rheumatol (1995) 1.31
Wegener's autoantigen decoded. Nature (1990) 1.31
CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax (2001) 1.24
Blount disease (tibia vara): another skeletal disorder associated with childhood obesity. J Pediatr (1982) 1.19
Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol (2003) 1.19
Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest (1991) 1.18
Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood (1993) 1.18
Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J (1997) 1.18
Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol (2001) 1.17
Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet (2006) 1.16
Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol (1996) 1.13
Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol (2000) 1.13
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med (1996) 1.12
Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) (2001) 1.12
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum (1995) 1.11
Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis (2005) 1.10
MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis (2008) 1.10
Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis (2004) 1.08
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods (1996) 1.08
A new V gene expressed in lambda-2 light chains of the mouse. Eur J Immunol (1987) 1.08
Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med (1996) 1.08
Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) (2004) 1.08
Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax (1997) 1.07
The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann Rheum Dis (2007) 1.06
Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest (1998) 1.06
[Anticytoplasmic antibodies as serological markers and activity parameters of Wegener's granulomatosis. A prospective study]. Dtsch Med Wochenschr (1988) 1.06
[Appropriate representation of rheumatology in the G-DRG system]. Z Rheumatol (2004) 1.05
Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum (1998) 1.05
Autoantibodies to cartilage collagens in relapsing polychondritis. Arch Dermatol Res (1993) 1.05
Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet (1999) 1.05
Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol (2000) 1.05
B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis (2005) 1.04
A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) (2002) 1.04
Serum antibodies to Klebsiella capsular polysaccharides in ankylosing spondylitis. Arthritis Rheum (1994) 1.04
Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis (2011) 1.03
Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun (2009) 1.03
Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum (1994) 1.03
Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum (2001) 1.03
Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis (2010) 1.02
Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med (1998) 1.02
Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol (2004) 1.01
Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin Exp Immunol (1996) 1.01
Association of UCP2 -866 G/A polymorphism with chronic inflammatory diseases. Genes Immun (2009) 1.01
A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol (2007) 1.00
Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol (2001) 1.00
High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med (1997) 1.00
[A new training program--a status report: vasculitis]. Z Rheumatol (2005) 1.00
Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci (2005) 0.99
Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int (1996) 0.99
Detection of immunoglobulin heavy-chain gene rearrangement at the single-cell level in malignant lymphomas: no rearrangement is found in Hodgkin and Reed-Sternberg cells. Int J Cancer (1994) 0.99
Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J (1999) 0.98
Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity? Rheumatology (Oxford) (2008) 0.97
[Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?]. Internist (Berl) (2005) 0.97
In vivo generation and function of B cells in the presence of a monoclonal anti-IgM antibody: implications for B cell tolerance. Eur J Immunol (1987) 0.97
Periostitis as the initial manifestation of systemic vasculitis. Ann Rheum Dis (2005) 0.97
Immunoglobulin heavy and light chain gene sequences of a human CD5 positive immunocytoma and sequences of four novel VHIII germline genes. Immunol Lett (1992) 0.96
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure]. Z Rheumatol (1996) 0.96
No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford) (2002) 0.96
Immunopathology of ANCA-associated vasculitis. Intern Med (1999) 0.96
[Academy for Graduate and Continuing Education in Rheumatology]. Z Rheumatol (2004) 0.96